Teclison is a clinical-stage biotechnology company developing innovative cancer therapeutics to induce tumor necrosis and enhance anti-tumor immunity. The company's portfolio is comprised of new approaches aimed at enhancing the therapeutic benefit of tumor embolization and immunotherapy to treat nearly all solid cancers.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/14/22 | $5,900,000 |
Nestor Capital W.T.T. Investment  | undisclosed |
